Appointment of Broker

Oxford Biomedica PLC
18 August 2004


FOR IMMEDIATE RELEASE                                            18 August 2004


                              OXFORD BIOMEDICA PLC

                              Appointment of Broker


Oxford, UK: 18 August 2004 - Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, is pleased to announce the appointment of Panmure Gordon, a
division of Lazard & Co., Limited, as its broker with immediate effect.


                                     -Ends-

For further information, please contact:

Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive               Tel: [phone]

Panmure Gordon:
Tim Linacre                                            Tel: [phone]

City/Financial Enquiries:
Lisa Baderoon/ Mark Court: Buchanan Communications     Tel: [phone]


Notes to editors

Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange. In addition
to its technical expertise in gene delivery, Oxford BioMedica has in-house
clinical, regulatory and manufacturing know-how. The development pipeline
includes two novel anti-cancer products in clinical trials; and two neurotherapy
products in advanced preclinical development for Parkinson's disease and
retinopathy. The Company is underpinned by an extensive preclinical and research
portfolio and about 70 patent families, which represents one of the broadest
patent estates in the field. The Company has a staff of about 65 split between
its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in
San Diego, California. Oxford. BioMedica has corporate collaborations with
Wyeth, Intervet, Viragen, Merck & Co, Amersham and Kiadis.


Further information is available at http://www.oxfordbiomedica.co.uk.



                      This information is provided by RNS
            The company news service from the London Stock Exchange